Notice: This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NITE vs. SRRK, ALVO, ADMA, ACLX, IMVT, CRSP, DNLI, VCEL, TWST, and KYMRShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Scholar Rock (SRRK), Alvotech (ALVO), ADMA Biologics (ADMA), Arcellx (ACLX), Immunovant (IMVT), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Vericel (VCEL), Twist Bioscience (TWST), and Kymera Therapeutics (KYMR). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Scholar Rock Alvotech ADMA Biologics Arcellx Immunovant CRISPR Therapeutics Denali Therapeutics Vericel Twist Bioscience Kymera Therapeutics Scholar Rock (NASDAQ:SRRK) and Nightstar Therapeutics (NASDAQ:NITE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking. Does the media refer more to SRRK or NITE? In the previous week, Scholar Rock had 12 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 12 mentions for Scholar Rock and 0 mentions for Nightstar Therapeutics. Scholar Rock's average media sentiment score of 0.77 beat Nightstar Therapeutics' score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media. Company Overall Sentiment Scholar Rock Positive Nightstar Therapeutics Neutral Which has preferable earnings and valuation, SRRK or NITE? Nightstar Therapeutics has lower revenue, but higher earnings than Scholar Rock. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M113.95-$165.79M-$2.35-17.19Nightstar TherapeuticsN/AN/A-$36.86M-$1.26-24.50 Do institutionals and insiders hold more shares of SRRK or NITE? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 32.8% of Nightstar Therapeutics shares are held by institutional investors. 19.2% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in SRRK or NITE? Nightstar Therapeutics received 58 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 69.88% of users gave Nightstar Therapeutics an outperform vote while only 66.01% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16766.01% Underperform Votes8633.99% Nightstar TherapeuticsOutperform Votes22569.88% Underperform Votes9730.12% Do analysts prefer SRRK or NITE? Scholar Rock currently has a consensus price target of $40.43, indicating a potential upside of 0.07%. Given Scholar Rock's stronger consensus rating and higher probable upside, research analysts plainly believe Scholar Rock is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SRRK or NITE more profitable? Nightstar Therapeutics' return on equity of -30.89% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -145.60% -91.83% Nightstar Therapeutics N/A -30.89%-27.65% Which has more risk and volatility, SRRK or NITE? Scholar Rock has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Nightstar Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. SummaryScholar Rock beats Nightstar Therapeutics on 10 of the 17 factors compared between the two stocks. Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$3.09B$5.61B$9.14BDividend YieldN/A1.87%5.36%3.98%P/E Ratio-24.5046.7489.6917.66Price / SalesN/A297.571,219.4081.09Price / CashN/A188.8944.3437.71Price / Book5.244.145.134.73Net Income-$36.86M-$40.99M$118.85M$225.42M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$30.87-0.4%N/A+22.0%$1.04BN/A-24.5047SRRKScholar Rock3.304 of 5 stars$43.13-1.8%$40.43-6.3%+180.7%$4.04B$33.19M-18.35140Analyst ForecastNews CoverageALVOAlvotech3.0036 of 5 stars$13.27+0.3%$18.00+35.6%-17.6%$4.00B$93.38M-7.171,026Short Interest ↓ADMAADMA Biologics4.1804 of 5 stars$16.02-3.7%$21.25+32.6%+207.3%$3.79B$382.81M57.21530Short Interest ↑ACLXArcellx2.9838 of 5 stars$66.48-0.8%$105.93+59.3%+0.3%$3.60B$110.32M-93.6380Short Interest ↑IMVTImmunovant1.7639 of 5 stars$23.86+0.3%$47.00+97.0%-44.6%$3.50BN/A-10.75120CRSPCRISPR Therapeutics2.6756 of 5 stars$40.53+0.6%$78.38+93.4%-37.4%$3.46B$371.21M-14.32473Short Interest ↑News CoverageGap UpDNLIDenali Therapeutics4.4791 of 5 stars$21.93+1.2%$38.91+77.4%+33.6%$3.16B$330.53M-7.95430Analyst ForecastShort Interest ↑VCELVericel2.3264 of 5 stars$59.07+4.8%$62.14+5.2%+32.4%$2.92B$197.52M984.66300Insider TradeTWSTTwist Bioscience2.5907 of 5 stars$47.56+3.7%$51.90+9.1%+42.4%$2.82B$312.97M-13.21990Upcoming EarningsInsider TradeNews CoverageKYMRKymera Therapeutics2.555 of 5 stars$40.61+0.8%$55.38+36.4%+20.9%$2.63B$78.59M-17.35170 Related Companies and Tools Related Companies SRRK Alternatives ALVO Alternatives ADMA Alternatives ACLX Alternatives IMVT Alternatives CRSP Alternatives DNLI Alternatives VCEL Alternatives TWST Alternatives KYMR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NITE) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
